Evidence map›Paper›PMID 35117707›Full record

ArticleTranslational cancer research2020

Tumor-derived exosomes facilitate tumor cells escape from drug therapy in clear cell renal cell carcinoma.

Xiaogang Wang, Qianqian Shi, Li Cui, Kai Wang, Pengfeng Gong, Xiaozhou He, Renfang Xu, Mingdian Tan, Yunjie Cao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Extracellular Vesicles (EVs) in Tumor Diagnosis and Therapy.Technology in cancer research & treatment
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xiaogang Wang *Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Qianqian Shi *Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Li CuiDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Kai WangDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Pengfeng GongDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Xiaozhou HeDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Renfang XuDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Mingdian TanTongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
Yunjie CaoDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
Soochow University · CNShanghai Tenth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is one of the most prevalent cancers in renal cancer patients. Currently, mTOR and vascular endothelial growth factor (VEGF) inhibitors are the main targets of clinical drugs used to treat ccRCC. However, the major clinical challenge with these treatments is drug resistance. So far, the mechanisms of drug resistance in cancer are not fully understood.

methodsWe applied tumor-derived exosomes to treat renal cells to detect the survival rate after co-treated with anti-tumor drugs-TNFα, mammalian target of rapamycin (mTOR) inhibitor or STAT3 inhibitor. Meanwhile, we also detected the expression change in the protein level related to the proliferation and exosome secretion.

resultsExosomes derived from renal carcinoma cells facilitate resistance in tumors cells when given drug therapy via the mTOR-ERK-STAT-NF-κB signaling pathway.

conclusionsOur results provide new insights on tumor cells resistance to drug therapies in general, and that exosomes could be the potential targets in treatment of ccRCC in future clinical therapy.

Indexed as

clear cell renal cell carcinoma (ccRCC)drug resistanceExosomesmammalian target of rapamycin (mTOR)

Identifiers

PMID35117707
PMCPMC8798292
OpenAlexW3021827995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.